SecBot SecBot
SECBOTREPLAY Home › Report › GTBP

GTBP · GT Biopharma entered into a securities purchase agreement to sell up to…

GT Biopharma, Inc. · 8-K filed Sep 15, 2026 at 08:57 ET

At the news

BEARISHIMPACT 7/10

8-K filed Sep 15, 2026 at 08:57 ET

GT Biopharma entered into a securities purchase agreement to sell up to 41,778 shares of Series M 10% Convertible Preferred Stock and warrants for gross proceeds of up to $8,277,778 ($7,450,000 net after a 10% original issue discount). The offering includes a $30M greenshoe option and is highly dilutive, with a conversion/exercise price of $6.10 per share, subject to further price resets. The company also filed a Certificate of Designation for the preferred stock and a Registration Rights Agreement. This is a distressed financing by a micro-cap biotech with a $21M market cap, signaling acute capital needs and severe dilution risk for common shareholders.

  • Company sold up to 41,778 shares of Series M 10% Convertible Preferred Stock for aggregate gross proceeds of up to $8,277,778 (net $7,450,000 after 10% OID).
  • Investors receive common stock warrants for 100% of conversion shares, exercisable at $6.10 for 5 years.
  • Greenshoe option allows investors to purchase up to an additional $33.3M stated value of preferred stock ($30M purchase price).
  • Conversion price of $6.10 is subject to further downward adjustment via a price reset mechanism tied to Greenshoe exercises, with a floor of $1.282.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access